ID: ALA304765

Max Phase: Preclinical

Molecular Formula: C14H14N3O11PS2

Molecular Weight: 495.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nc(/N=N/c2cc(S(=O)(=O)O)ccc2S(=O)(=O)O)c2c(c1O)COP(=O)(O)OC2

Standard InChI:  InChI=1S/C14H14N3O11PS2/c1-7-13(18)9-5-27-29(19,20)28-6-10(9)14(15-7)17-16-11-4-8(30(21,22)23)2-3-12(11)31(24,25)26/h2-4,18H,5-6H2,1H3,(H,19,20)(H,21,22,23)(H,24,25,26)/b17-16+

Standard InChI Key:  GGJCEYXTBFQGRQ-WUKNDPDISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 495.38

Molecular Weight (Monoisotopic): 494.9807

AlogP: 2.15

#Rotatable Bonds: 4

Polar Surface Area: 222.34

Molecular Species: ACID

HBA: 11

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 14

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: -3.20

CX Basic pKa: 1.07

CX LogP: -3.93

CX LogD: -6.33

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.27

Np Likeness Score: -0.27

References

1. Jacobson KA, Kim YC, Wildman SS, Mohanram A, Harden TK, Boyer JL, King BF, Burnstock G..  (1998)  A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.,  41  (13): [PMID:9632352] [10.1021/jm980183o]

2. Kim YC, Brown SG, Harden TK, Boyer JL, Dubyak G, King BF, Burnstock G, Jacobson KA..  (2001)  Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.,  44  (3): [PMID:11462975] [10.1021/jm9904203]

Source

Source(1):

• Scientific Literature